APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Drugs (Anti-obesity Medication)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anti-Obesity Drugs (Anti-obesity Medication) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchAnti-Obesity Drugs (Anti-obesity Medication) Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Drugs (Anti-obesity Medication) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Drugs (Anti-obesity Medication) Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Anti-Obesity Drugs (Anti-obesity Medication) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anti-Obesity Drugs (Anti-obesity Medication) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-Obesity Drugs (Anti-obesity Medication) include Eisai, Sanofi, Novo Nordisk, Merck, F.Hoffmann-La Roche, Pfizer, GlaxoSmithKline, Bayer AG and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Obesity Drugs (Anti-obesity Medication) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Obesity Drugs (Anti-obesity Medication) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Obesity Drugs (Anti-obesity Medication) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Obesity Drugs (Anti-obesity Medication) market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Company

Eisai

Sanofi

Novo Nordisk

Merck

F.Hoffmann-La Roche

Pfizer

GlaxoSmithKline

Bayer AG

AstraZeneca

Zafgan

Vivus

Shionogi

Rhythm Pharmaceuticals

Orexigen Therapeutics

Norgine

Boehringer Ingelheim

Arena Pharmaceuticals

Amylin

Alizyme

Alizyme

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Type

Rx Drug

OTC Drug

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Application

Middle Aged (41-60)

Juvenile (7-17)

Youth (18-40)

Elderly (Above 60)

Childhood (0-6)

Anti-Obesity Drugs (Anti-obesity Medication) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Drugs (Anti-obesity Medication) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Drugs (Anti-obesity Medication) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Drugs (Anti-obesity Medication).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Obesity Drugs (Anti-obesity Medication) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-Obesity Drugs (Anti-obesity Medication) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anti-Obesity Drugs (Anti-obesity Medication) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anti-Obesity Drugs (Anti-obesity Medication) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends Table 2. Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers Table 3. Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges Table 4. Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints Table 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers Table 9. Global Anti-Obesity Drugs (Anti-obesity Medication) Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anti-Obesity Drugs (Anti-obesity Medication) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers, Product Type & Application Table 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Obesity Drugs (Anti-obesity Medication) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rx Drug Table 17. Major Manufacturers of OTC Drug Table 18. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2026) & (k units) Table 20. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2027-2032) & (k units) Table 21. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2026) Table 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2027-2032) Table 23. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2026) & (k units) Table 25. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2027-2032) & (k units) Table 26. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2026) Table 27. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Middle Aged (41-60) Table 29. Major Manufacturers of Juvenile (7-17) Table 30. Major Manufacturers of Youth (18-40) Table 31. Major Manufacturers of Elderly (Above 60) Table 32. Major Manufacturers of Childhood (0-6) Table 33. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2026) & (k units) Table 35. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2027-2032) & (k units) Table 36. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2026) Table 37. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2027-2032) Table 38. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2026) & (k units) Table 40. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2027-2032) & (k units) Table 41. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2026) Table 42. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2027-2032) Table 43. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2026) & (k units) Table 45. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2021-2026) Table 46. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 50. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 51. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 53. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2027-2032) & (k units) Table 60. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2021-2026) Table 64. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2027-2032) Table 65. Eisai Company Information Table 66. Eisai Business Overview Table 67. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 69. Eisai Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 74. Sanofi Recent Development Table 75. Novo Nordisk Company Information Table 76. Novo Nordisk Business Overview Table 77. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 79. Novo Nordisk Recent Development Table 80. Merck Company Information Table 81. Merck Business Overview Table 82. Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 84. Merck Recent Development Table 85. F.Hoffmann-La Roche Company Information Table 86. F.Hoffmann-La Roche Business Overview Table 87. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 89. F.Hoffmann-La Roche Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 94. Pfizer Recent Development Table 95. GlaxoSmithKline Company Information Table 96. GlaxoSmithKline Business Overview Table 97. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 99. GlaxoSmithKline Recent Development Table 100. Bayer AG Company Information Table 101. Bayer AG Business Overview Table 102. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 104. Bayer AG Recent Development Table 105. AstraZeneca Company Information Table 106. AstraZeneca Business Overview Table 107. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 109. AstraZeneca Recent Development Table 110. Zafgan Company Information Table 111. Zafgan Business Overview Table 112. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 114. Zafgan Recent Development Table 115. Vivus Company Information Table 116. Vivus Business Overview Table 117. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 119. Vivus Recent Development Table 120. Shionogi Company Information Table 121. Shionogi Business Overview Table 122. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 124. Shionogi Recent Development Table 125. Rhythm Pharmaceuticals Company Information Table 126. Rhythm Pharmaceuticals Business Overview Table 127. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 129. Rhythm Pharmaceuticals Recent Development Table 130. Orexigen Therapeutics Company Information Table 131. Orexigen Therapeutics Business Overview Table 132. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 134. Orexigen Therapeutics Recent Development Table 135. Norgine Company Information Table 136. Norgine Business Overview Table 137. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 139. Norgine Recent Development Table 140. Boehringer Ingelheim Company Information Table 141. Boehringer Ingelheim Business Overview Table 142. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 144. Boehringer Ingelheim Recent Development Table 145. Arena Pharmaceuticals Company Information Table 146. Arena Pharmaceuticals Business Overview Table 147. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 149. Arena Pharmaceuticals Recent Development Table 150. Amylin Company Information Table 151. Amylin Business Overview Table 152. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 154. Amylin Recent Development Table 155. Alizyme Company Information Table 156. Alizyme Business Overview Table 157. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 159. Alizyme Recent Development Table 160. Alizyme Company Information Table 161. Alizyme Business Overview Table 162. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio Table 164. Alizyme Recent Development Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Anti-Obesity Drugs (Anti-obesity Medication) Distributors List Table 168. Anti-Obesity Drugs (Anti-obesity Medication) Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Anti-Obesity Drugs (Anti-obesity Medication) Product Image Figure 2. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2021-2032) & (k units) Figure 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anti-Obesity Drugs (Anti-obesity Medication) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rx Drug Image Figure 9. OTC Drug Image Figure 10. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2032) Figure 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2032) Figure 16. Middle Aged (41-60) Image Figure 17. Juvenile (7-17) Image Figure 18. Youth (18-40) Image Figure 19. Elderly (Above 60) Image Figure 20. Childhood (0-6) Image Figure 21. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2032) Figure 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2032) Figure 27. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 29. U.S. Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 34. Germany Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 41. China Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2021-2032) Figure 49. Brazil Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Anti-Obesity Drugs (Anti-obesity Medication) Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Figure 60. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Figure 62. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Rx Drug
  • OTC Drug
Applications
  • Middle Aged (41-60)
  • Juvenile (7-17)
  • Youth (18-40)
  • Elderly (Above 60)
  • Childhood (0-6)
Companies covered
  • Eisai
  • Sanofi
  • Novo Nordisk
  • Merck
  • F.Hoffmann-La Roche
  • Pfizer
  • GlaxoSmithKline
  • Bayer AG
  • AstraZeneca
  • Zafgan
  • Vivus
  • Shionogi
  • Rhythm Pharmaceuticals
  • Orexigen Therapeutics
  • Norgine
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Amylin
  • Alizyme
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Dynamics
  1. 2.1 Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends
  2. 2.2 Anti-Obesity Drugs (Anti-obesity Medication) Industry Drivers
  3. 2.3 Anti-Obesity Drugs (Anti-obesity Medication) Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Drugs (Anti-obesity Medication) Industry Restraints
3 Anti-Obesity Drugs (Anti-obesity Medication) Market by Manufacturers
  1. 3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-Obesity Drugs (Anti-obesity Medication) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers, Product Type & Application
  7. 3.7 Global Anti-Obesity Drugs (Anti-obesity Medication) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-Obesity Drugs (Anti-obesity Medication) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-Obesity Drugs (Anti-obesity Medication) Tier 1, Tier 2, and Tier 3
4 Anti-Obesity Drugs (Anti-obesity Medication) Market by Type
  1. 4.1 Anti-Obesity Drugs (Anti-obesity Medication) Type Introduction
  2. 4.1.1 Rx Drug
  3. 4.1.2 OTC Drug
  4. 4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type
  5. 4.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2021-2032)
  7. 4.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type
  9. 4.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2021-2032)
  11. 4.3.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2021-2032)
5 Anti-Obesity Drugs (Anti-obesity Medication) Market by Application
  1. 5.1 Anti-Obesity Drugs (Anti-obesity Medication) Application Introduction
  2. 5.1.1 Middle Aged (41-60)
  3. 5.1.2 Juvenile (7-17)
  4. 5.1.3 Youth (18-40)
  5. 5.1.4 Elderly (Above 60)
  6. 5.1.5 Childhood (0-6)
  7. 5.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application
  8. 5.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2021-2032)
  10. 5.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2021-2032)
  11. 5.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application
  12. 5.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2021-2032)
  14. 5.3.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2021-2032)
6 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region
  1. 6.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2021-2026)
  4. 6.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region
  1. 7.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region
  2. 7.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2021-2026)
  4. 7.1.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2027-2032)
  5. 7.1.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032)
  8. 7.2.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032)
  11. 7.3.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novo Nordisk
  14. 8.3.1 Novo Nordisk Company Information
  15. 8.3.2 Novo Nordisk Business Overview
  16. 8.3.3 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  18. 8.3.5 Novo Nordisk Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 F.Hoffmann-La Roche
  26. 8.5.1 F.Hoffmann-La Roche Company Information
  27. 8.5.2 F.Hoffmann-La Roche Business Overview
  28. 8.5.3 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  30. 8.5.5 F.Hoffmann-La Roche Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Bayer AG
  44. 8.8.1 Bayer AG Company Information
  45. 8.8.2 Bayer AG Business Overview
  46. 8.8.3 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  48. 8.8.5 Bayer AG Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Zafgan
  56. 8.10.1 Zafgan Company Information
  57. 8.10.2 Zafgan Business Overview
  58. 8.10.3 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  60. 8.10.5 Zafgan Recent Developments
  61. 8.11 Vivus
  62. 8.11.1 Vivus Company Information
  63. 8.11.2 Vivus Business Overview
  64. 8.11.3 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  66. 8.11.5 Vivus Recent Developments
  67. 8.12 Shionogi
  68. 8.12.1 Shionogi Company Information
  69. 8.12.2 Shionogi Business Overview
  70. 8.12.3 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  72. 8.12.5 Shionogi Recent Developments
  73. 8.13 Rhythm Pharmaceuticals
  74. 8.13.1 Rhythm Pharmaceuticals Company Information
  75. 8.13.2 Rhythm Pharmaceuticals Business Overview
  76. 8.13.3 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  78. 8.13.5 Rhythm Pharmaceuticals Recent Developments
  79. 8.14 Orexigen Therapeutics
  80. 8.14.1 Orexigen Therapeutics Company Information
  81. 8.14.2 Orexigen Therapeutics Business Overview
  82. 8.14.3 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  84. 8.14.5 Orexigen Therapeutics Recent Developments
  85. 8.15 Norgine
  86. 8.15.1 Norgine Company Information
  87. 8.15.2 Norgine Business Overview
  88. 8.15.3 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  90. 8.15.5 Norgine Recent Developments
  91. 8.16 Boehringer Ingelheim
  92. 8.16.1 Boehringer Ingelheim Company Information
  93. 8.16.2 Boehringer Ingelheim Business Overview
  94. 8.16.3 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  96. 8.16.5 Boehringer Ingelheim Recent Developments
  97. 8.17 Arena Pharmaceuticals
  98. 8.17.1 Arena Pharmaceuticals Company Information
  99. 8.17.2 Arena Pharmaceuticals Business Overview
  100. 8.17.3 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  102. 8.17.5 Arena Pharmaceuticals Recent Developments
  103. 8.18 Amylin
  104. 8.18.1 Amylin Company Information
  105. 8.18.2 Amylin Business Overview
  106. 8.18.3 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  108. 8.18.5 Amylin Recent Developments
  109. 8.19 Alizyme
  110. 8.19.1 Alizyme Company Information
  111. 8.19.2 Alizyme Business Overview
  112. 8.19.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  114. 8.19.5 Alizyme Recent Developments
  115. 8.20 Alizyme
  116. 8.20.1 Alizyme Company Information
  117. 8.20.2 Alizyme Business Overview
  118. 8.20.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
  120. 8.20.5 Alizyme Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Obesity Drugs (Anti-obesity Medication) Value Chain Analysis
  2. 9.1.1 Anti-Obesity Drugs (Anti-obesity Medication) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process
  6. 9.2 Anti-Obesity Drugs (Anti-obesity Medication) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Obesity Drugs (Anti-obesity Medication) Distributors
  9. 9.2.3 Anti-Obesity Drugs (Anti-obesity Medication) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst